ANXA1 and myeloid sarcoma: Another study pointed to the potential therapeutic benefit of annexin-1 administration in MS, as intracerebroventricular administration in EAE rats significantly reduced neurological severity, and immunoneutralization of endogenous brain annexin-1 failed to exacerbate the clinical features of EAE [65].